

---

## Murtaza K. Adam, MD

---

255 S Routt Street, Suite 200, Lakewood, CO 80228  
(303) 261-1600

---

### Current Position

---

Partner Physician, 2017 – Present  
Colorado Retina Associates, Denver, CO

Chair of Clinical Research Committee, 2021 – Present  
Colorado Retina Associates, Denver, CO

Adjunct Clinical Associate Professor, 2019 – Present  
Rocky Vista University, Parker, CO

---

### Board Certification

---

American Board of Ophthalmology, October 2017  
American Board of Medical Specialties, Chicago, IL

---

### Post-Doctoral Training

---

Fellowship, July 2015 – June 2017  
Vitreoretinal Surgery, Wills Eye Hospital/Mid Atlantic Retina

Residency, July 2012 – June 2015  
Ophthalmology, Wills Eye Hospital  
*Co-Chief Resident, May 2014 – May 2015*

Internship, July 2011 – June 2012  
Transitional Year Program, Aurora St. Luke's Medical Center

---

### Education

---

Medical Degree, May 2011  
Medical College of Wisconsin

Bachelor of Biomedical Engineering, May 2007  
University of Minnesota – Twin Cities

Bachelor of Arts in Physiology, May 2007  
University of Minnesota – Twin Cities

---

### Honors / Awards / Grants

---

One to Watch Honoree, 2023  
Retina Today and Allergan Retina

Honor Award, 2022  
American Society of Retina Specialists

H. Dunbar Hoskins, Jr MD Center for Quality Eye Care IRIS Registry Research Fund Grant, 2021  
American Academy of Ophthalmology

Rising Star, 2021  
Castle Connolly

Fostering Innovating Retina Stars of Tomorrow (FIRST) Program, 2018  
Allergan Retina

William Tasman, MD Outstanding Fellow Award, 2017  
Wills Eye Hospital

Investigator Initiated Trial Grant, 2017  
Alcon Laboratories, Inc.

Heed Fellowship, 2015 – 2016  
Heed Ophthalmic Foundation

Wills Eye Hospital Innovation Grant Awards, 2015  
Telemedicine and Retina

James S. Shipman Award for Best Resident Scientific Presentation, 2014  
Wills Eye Hospital 66<sup>th</sup> Annual Conference

Best Mystery Case Presentation, 2014  
Atlantic Coast Retina Club

Wills Eye Hospital Innovation Grant Award, 2014  
Diagnostics

Wills Eye Hospital Innovation Grant Awards, 2013  
Diagnostics, Neuro-ophthalmology, and Retina

Alpha Omega Alpha Honor Medical Society, 2010  
Medical College of Wisconsin

Medical Student Summer Research Program Grant Recipient, 2008  
Medical College of Wisconsin

Undergraduate Research Opportunities Program Grant Recipient, 2006 – 2007  
University of Minnesota – Twin Cities

Institute of Technology Merit Scholarship, 2006 – 2007  
University of Minnesota – Twin Cities

Tau Beta Pi National Engineering Honor Society, 2006 – 2007  
University of Minnesota – Twin Cities

Institute of Technology Dean's List, 2005 – 2007  
University of Minnesota – Twin Cities

AP Scholar Award Recipient with Honor, 2002  
College Board

---

**Professional Activities / Volunteer Work / Medical Education**

---

Board Member, 2022 – Present  
Colorado Society of Eye Physicians and Surgeons

Research Advisory Board Member, 2020 – Present  
US Retina

Telemedicine Retinal Consultant, 2020 – Present  
Global Eye Project

Volunteer Physician  
Colorado Coalition for the Homeless, 2019 – Present

Member, 2017 – Present  
The Retina Society, American Society of Retina Specialists, American Academy of Ophthalmology,  
Colorado Society of Eye Physicians and Surgeons, and Colorado Medical Society

Medical Chair, 2017  
Denver VisionWalk, Foundation for Fighting Blindness

Reviewer, 2014 – Present  
Ophthalmology, Ophthalmology Retina, British Journal of Ophthalmology, Clinical and Experimental  
Ophthalmology, Retina, Ophthalmic Genetics, Translational Vision Science and Technology, Survey  
of Ophthalmology, Frontiers in Medicine

Co-Chief Resident, 2014 – 2015  
Wills Eye Residency Program

Visiting Research Fellow, 2015  
Wills International Resident Experience Program, University of Yamanashi, Japan

PGY-2 Class Representative, 2013 – 2014  
Wills Eye Residency Program

Global Impact Fellow, 2011  
Unite for Sight Global Health Program, Accra, Ghana

USMLE Step 1 Tutor, 2009 – 2010  
Medical College of Wisconsin Student Assembly

Facilities Committee Member, 2010 –2010  
LCME Accreditation Student Self Study Committee

President, 2007 – 2009  
Medical College of Wisconsin Student Bioethics Interest Group

Class Representative (M1) / Research Affairs Representative (M2), 2007 – 2009  
Medical College of Wisconsin Student Assembly

---

## Clinical Trials

---

1. Atmosphere (Regnxbio), Protocol: RGX-314-2104. **Principal Investigator**. A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. 2022 – Present.
2. Pavilion (Genentech), Protocol:GR41675, **Principal Investigator**, A Phase III, Multicenter, Randomized, study of the efficacy, safety, and Pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Retinopathy. 2020-Present.
3. Infinity (Adverum), Protocol: ADVM-022, **Sub-Investigator**, A Phase 2, multi-center, randomized, double-masked, active controlled study of ADVM-022 (AAV.7m8-aflibercept) in subjects with Diabetic Macular Edema. 2020-Present.
4. Regatta (Gemini Therapeutics), Protocol: GEM-CL-10302, **Sub-Investigator**, A Multicenter, Open-label, Multiple dose study in patients with Geographic Atrophy secondary to Dry Age-Related Macular degeneration to evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103. 2020-Present.
5. Gather2 (IVERIC), Protocol: ISEE2008, **Sub-Investigator**, A Phase 3 Multicenter, Randomized, Double-Masked, Sham-controlled clinical trial to assess the safety and efficacy of intravitreal administration of ZIMURA™ (Complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related macular degeneration. 2020-Present.
6. Amgen (Amgen, Inc), Protocol: 20170542, **Sub-Investigator**, A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety compared to Aflibercept (Eylea) in subjects with Neovascular age-related macular degeneration. 2020-Present.
7. Photon (Regeneron), Protocol: VGFTe-HD-DME-1934, **Sub-Investigator**, A Randomized, Double-masked, Active-controlled Phase 2/3 study of the efficacy and safety of high-dose Aflibercept in patients with Diabetic Macular Edema. 2020-Present.
8. Rhone-X (Genentech), Protocol: GR41987, **Sub-Investigator**, A Multicenter, Open-Label Extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema. 2020-Present.
9. Catalina (NGM Bio), Protocol: NGM621-GA-201, **Sub-Investigator**, A Phase 2 Multicenter, Randomized, Double-masked, Sham-Controlled study of the Safety and efficacy of intravitreal injections of NGM621 in subjects with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). 2020-Present.
10. Pagoda (Genentech), Protocol: GR40550, **Principal Investigator**, A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema, 2020-Present.
11. Archway (Genentech), Protocol: GR40548, **Principal Investigator**, Title: A Phase III, Multicenter, Randomized, Visual Assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Neovascular age-related macular degeneration. 2018 – Present.
12. Portal (Genentech), Protocol: GR40549, **Sub-Investigator**, Title: A Multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in patients with Neovascular age-related macular degeneration. 2018 – Present.
13. Ladder (Genentech), Protocol: GX28228, **Sub-Investigator**, Title: Active Treatment Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of

- Ranibizumab in Patients with Sub-foveal Neovascular Age-Related Macular Degeneration. 2015 – 2019.
14. Panorama (Regeneron), Protocol: VGFTe-OD-1411, **Sub-Investigator**, Title: A phase 3, double-masked, randomized study of the efficacy and safety of intravitreal Aflibercept injections in patients with Moderately severe to severe Nonproliferative Diabetic Retinopathy. 2015 – 2019.
  15. Maple (Allergan), Protocol 1771-201-008, **Sub-Investigator**, Title: A multicenter, open-label, single-arm study to evaluate Abicpar for safety and treatment effect in patients with Neovascular age-related macular degeneration (AMD) 2018 – 2019.
  16. HAWK Extension (Alcon), Protocol: RTH258-C001, **Sub-Investigator**, Title: A Two-year Randomized, Double-Masked, Multicenter, Three-Arm Study comparing the efficacy and safety of RTH258 versus Aflibercept in subject with Neovascular Age-Related Macular Degeneration who participated in Hawk 1. 2017 – 2018.
  17. Sapphire (Clearside Biomedical), Protocol: CLS1003-301, **Sub-Investigator**, Title: A Randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal Aflibercept in subjects with retinal vein occlusion. 2016 – 2019.
  18. Gilead, **Sub-Investigator**, Title: A Phase 2, randomized, placebo-controlled trial evaluating the efficacy and safety of Filgotinib in subjects with Active Noninfectious uveitis. 2018 – Present.
  19. Opthea, Protocol: OPT-302, **Sub-Investigator**, A dose-ranging study of intravitreal OPT-302 in combination with Ranibizumab in participants with wet AMD. 2018 – Present.
  20. OPH2003B (Ophotech), **Sub-investigator**, Title: A Phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of Intravitreal Administration of Zimura (Anti-C5 Aptamer) in subjects with Geographic atrophy secondary to Dry Age-Related Macular Degeneration. 2018 – Present.
  21. OPH2007 (Ophotech), **Sub-Investigator**, Title: A Phase 2A open-label study to assess the safety of Zimura (Anti-C5 Aptamer) administered in combination with Lucentis 0.5mg in patients with Neovascular age-related Macular Degeneration. 2018 – 2019.
  22. Lucerne (Genentech), **Sub-Investigator**, Title: A Phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Neovascular Age-Related Macular Degeneration 2019- Present.
  23. Panda (Chengdu Kanghong), **Sub-Investigator**, Title: A multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conercept intravitreal injection in subjects with Neovascular age-related macular degeneration. 2018-Present.
  24. Xplore (Xbrane), **Sub-Investigator**, A phase III double-blind, parallel group, multicenter study to compare the efficacy and safety of Xlucane versus Lucentis in patients with Neovascular age-related macular degeneration 2019-Present.
  25. Gallego (Genentech), **Sub-Investigator**, A Phase II, Multicenter, randomized, single-masked, Sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with Geographic Atrophy secondary to Age-Related macular Degeneration, 2019-Present.
  26. Adverum (Adverum Biotechnologies), **Sub-investigator**, An open Label Phase 1 study of ADV-022 (AAV.7m8-aflibercept) in Neovascular (Wet) age-related macular degeneration, 2019-Present.
  27. Avante (Santen), **Sub-Investigator**, A multicenter, randomized, double-masked and active controlled Phase II Study assessing the Efficacy and Safety of Intravitreal injections of DE-122 in combination with Lucentis compared to Lucentis Monotherapy in subjects with Wet Age-related macular Degeneration. 2018-2019.
  28. Lumina (Santen), **Sub-Investigator**, A Phase III, multicenter, sham-controlled, randomized, double-masked study assessing the efficacy and safety of Intravitreal injections of 44µg DE-109 for the treatment of Active, non-infectious uveitis of the posterior segment of the eye. 2019- Present.
  29. Merlin (Novartis), **Sub-Investigator**, A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolocizumab 6 mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid 2018-Present.
  30. ONS (Outlook), **Sub-Investigator**, A clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related. macular degeneration (AMD). 2019- Present.
  31. Panoptica (Panoptica, Inc), **Sub-Investigator**, A randomized, double-masked, uncontrolled, multicenter Phase I/II study to evaluate safety and tolerability of PAN-90806 Eye Drops, suspension

in treatment- Naïve participants with neovascular age-related macular degeneration (AMD). 2018-2019.

32. Apellis (Apellis Pharmaceuticals), **Sub-investigator**, A Phase III, multicenter, randomized double-masked, sham-controlled study to compare the efficacy and safety of Intravitreal APL-2 therapy with Sham injections in patients with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). 2018 – Present.

---

### Peer-Reviewed Publications

---

1. Lemon JD, Weiss SJ, **Adam, MK**. Reply: Droplless Protocol for Micro-Incision Vitrectomy Surgery: Shifting the Paradigm. *OSLI Retina*. 2023 Feb;54(2):123.
2. **Adam MK**, Podesto E. Octofluoropropane Gas Bubble within Macular Hole Following Attempted Repair. *JAMA Ophthalmology*. 2022 Apr 1;140(4):e215807.
3. **Adam MK**, Shahlaee A, Samara WA, Maguire JI, Ho AC, Hsu J. EN FACE VERSUS 12-LINE RADIAL OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS FOR DETECTION OF MACULAR FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. *Retinal Cases and Brief Reports*. 2020 Winter;14(1):53-60.
4. Lee CS, Hong B, Kasi S, Aderman C, Talcott K, **Adam MK**, Yue B, Akileswaran L, Nakamichi K, Wu Y, Rezaei KA, Olmos de Koo LC, Chee YE, Lee AY, Garg SJ, Van Gelder RN on behalf of the Endophthalmitis Study Group. Prognostic utility of whole genome sequencing and polymerase chain reaction tests of ocular fluids in post-procedural endophthalmitis. *American Journal of Ophthalmology*. 2020 Sep;217: 325-334.
5. **Adam MK**, Zheng CX, Fineman MF. Impact of Periocular Vibration Anesthesia on Pain Perceived During Intravitreal Injections. *Ophthalmology Retina*. 2020 Jan;4(1):113-115.
6. Huggins A, **Adam M**, Ehmann D, Eagle RC, Malloy B, Garg SJ. A CASE OF INTRAVESICAL BACILLUS CALMETTE-GUERIN-RELATED ENDOPHTHALMITIS AND RETINITIS CONFIRMED WITH RETINAL BIOPSY. *Retin Cases Brief Rep*. 2019 Fall;13(4):333-336.
7. Obeid A, Ehmann D, **Adam M**, Kasi S, Klufas M, Hsu J, Mehta S, Chiang A, Garg SJ, Gupta OG. Comparison of Residual Subfoveal Fluid By Intraoperative Optical Coherence Tomography After Macula Involving Rhegmatogenous Retinal Detachment Repair Using Direct Drainage, Drainage Retinotomy, or Pefluoro-n-Octane. *OSLI Retina*. 2019 Aug 1;50(8):497-503.
8. Weiss S, **Adam MK**, Gao X, Obeid A, Sivalingam AS, Garg SJ, Fineman MS, Haller J, Maguire JI, Fischer D, Hsu J. Letter to the Editor re: "Endophthalmitis Following Pars Plana Vitrectomy: Efficacy of Intraoperative Subconjunctival Antibiotics. *Retina*. 2019 Aug;39(8):e38-e39.
9. Thau A, Tsukikawa M, Wangtiraumnuy N, Capasso J, Affel E, Alnabi WA, **Adam M**, Alsulaiman SM, Spirn M, Levin AV. Optical Coherence Tomography in Knobloch Syndrome. *Ophthalmic Surg Lasers Imaging Retina*. 2019 Aug 1;50(8):e203-e210.
10. Gao X, Obeid A, Aderman CM, Talcott KE, Ali FS, **Adam MK**, Rovner BW, Hyman L, Ho AC, Hsu J. Loss to Follow-up After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema. *Ophthalmology Retina*. 2019 Mar;3(3):230-236.
11. Talcott KE, **Adam MK**, Soufi K, Aderman CM, Ali FS, Mellen PL, Garg SJ, Hsu J, Ho AC. Comparison of Three-Dimensional Heads-Up Display Platform to Standard Operating Microscope for Macular Surgery. *Ophthalmology Retina*. 2019 Mar; 3(3): 244-251.
12. Gao X, Obeid A, **Adam MK**, Hyman L, Ho AC, Hsu J. Loss to Follow-Up in Patients With Retinal Vein Occlusion Undergoing Intravitreal Anti-VEGF Injections. *OSLI Retina*. 2019 Mar 1;50(3):159-166.
13. Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, **Adam MK**, Kasi SK, Hyman L, Ho AC, Hsu J. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. *JAMA Ophthalmology*. 2018 Nov 1;136(11):1251-1259.
14. Weiss S, **Adam MK**, Gao X, Obeid A, Sivalingam AS, Garg SJ, Fineman MS, Haller J, Maguire JI, Fischer D, Hsu J. Endophthalmitis Following Pars Plana Vitrectomy: Efficacy of Intraoperative Subconjunctival Antibiotics. *Retina*. 2018 Sep;38(9):1848-1855.
15. McMahon JF, **Adam MK**, Dunn JP. Optical Coherence Tomography and Management of a Retinal Sarcoid Granuloma. *Ocular Immunology and Inflammation*. 2018 Aug 10:1-5.
16. Rahimy E, Pitcher JD, Hsu J, **Adam MK**, Samara WA, Shahlaee A, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS. A randomized double-blind placebo-control pilot study of

- Eplerenone for the treatment of Central Serous Chorioretinopathy (ECSELSIOR). *Retina*. 2018 May;38(5):962-969.
17. **Adam MK**, Weinstock B, Kasi SK, Ehmann DS, Garg SJ, Ho AC, Hsu J, Chiang A. Patient Comfort Using 577 nm Versus 532 nm Laser for Panretinal Photocoagulation. *Ophthalmology Retina*. 2018 Feb; 2(2):91-95.
  18. Joshi N, **Adam MK**, Samara W, Shahlaee A, Rahimy E, Hsu J, Fineman MS, Garg SJ. Optical Density of Subretinal Fluid in Patients with Chronic Central Serous Chorioretinopathy Treated with Eplerenone. *Journal of Vitreoretinal Diseases*. 2018 Jan; 2(1):6-11.
  19. Weiss S, **Adam MK**, Hsu J. En Face Optical Coherence Tomography of Stellate Nonhereditary Idiopathic Foveomacular Retinoschisis. *JAMA Ophthalmology*. 2017 Nov 9;135(11):e174280.
  20. Stephens D, **Adam MK**, Todorich B, Faia D, Dunn JP, Garg SJ, Mehta S. Optical Coherence Tomography Features of Endogenous Fungal Chorioretinitis and Endophthalmitis. *OSLI Retina*. 2017 Nov 1;48(11):894-901.
  21. Jenkins TL, **Adam MK**, Hsu J. Intraoperative Optical Coherence Tomography of an Inverted Internal Limiting Membrane Flap. *Ophthalmology*. 2017 Oct;124(10):1456.
  22. DeCroos FC, Reed D, **Adam MK**, Salz D, Gupta OP, Ho AC, Regillo CD. Reply. *American Journal of Ophthalmology*. 2017 Oct;182:205-206.
  23. Kasi SK, **Adam MK**, Ehmann DS. Bilateral Retinal Problem in a Patient With Alports Syndrome. *JAMA Ophthalmology*. 2017 Sep 1;135(9):995-996.
  24. **Adam MK**, Thornton S, Regillo CR, Park C, Ho AC, Hsu J. Minimal Endoillumination Levels and Display Luminous Emission During Three-Dimensional Heads-Up Vitreoretinal Surgery. *Retina*. 2017 Sep;37(9):1746-1749.
  25. DeCroos FC, Reed D, **Adam MK**, Salz D, Gupta OP, Ho AC, Regillo CD. Treat and extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. *American Journal of Ophthalmology*. 2017 Aug;180:142-150.
  26. Vahedi S, **Adam MK**, Dollin ML, Maguire JI. Trocar Cannula for Acute Endophthalmitis-related In-Office Vitreous Tap and Injection: Patient Comfort and Physician Ease-of-Use. *Retina*. 2017 Apr;37(4):657-661.
  27. Samara WA, Shahlaee WA, **Adam MK**, Khan AK, Chiang A, Maguire JI, Hsu J, Ho AC. Quantification of Diabetic Macular Ischemia using OCT Angiography and its Relationship with Visual Function. *Ophthalmology*. 2017 Feb;124(2):235-244.
  28. Kasi SK, Shahlaee A, **Adam MK**, Ehmann DS, Sivalingam A. Bilateral Occipital Pole Hypertensive Stroke Diagnosed with Macular Integrity Assessment (MAIA) Microperimetry. *Retinal Cases and Brief Reports*. 2017 Winter;11 Suppl 1:S170-S173.
  29. Ehmann DS, **Adam MK**, Kasi S, Sivalingam A, Dunn JP. Hemorrhagic Occlusive Vasculitis and Non-Hemorrhagic Vasculitis After Uncomplicated Cataract Surgery with Intracameral Vancomycin. *Retinal Cases and Brief Reports*. 2017 Winter;11 Suppl1:S155-S158.
  30. **Adam MK**, Aenchbacher W, Kurzweg T, Hsu J. Plenoptic Ophthalmoscopy: A Novel Imaging Technique. *OSLI Retina*. 2016 Nov1;47(11):1038-1043.
  31. Stephens D, Sridhar J, **Adam MK**. Projectile Intra-ocular Foreign Body in a Professional Glass Blower. *Ophthalmology*. 2016 May;123(5):1018.
  32. **Adam MK**, McMahon JF, Maguire JI, Spirn MJ. Funduscopy Screening of Fungemic Patients: Where We Stand. *Journal of Clinical and Experimental Ophthalmology*. 2016 Apr; 7(2):539-540.
  33. **Adam MK**, Rayess N, Rahimy E, Maguire JI, Hsu J. Radial Versus Raster Spectral-Domain Optical Coherence Tomography Scan Patterns for Detection of Neovascular Age-Related Degeneration Disease Activity. *British Journal of Ophthalmology*. 2016 Apr; 100(4):491-4.
  34. **Adam MK**, Rahimy E. Enhanced Depth Imaging Optical Coherence Tomography of Endogenous Fungal Chorioretinitis. *JAMA Ophthalmology*. 2015 Nov 12;133(11):e151931.
  35. **Adam MK**, Vahedi S, Nichols M, Fintelmann RE, Keenan JD, Garg SJ, Hsu J, Maguire JI, Spirn MJ. Inpatient Ophthalmology Consultation for Fungemia: Prevalence of Ocular Involvement and Necessity of Funduscopy Screening. *American Journal of Ophthalmology*. 2015 Nov;160(5):1078-1083.e2.
  36. **Adam MK**, Brady CJ, Flowers AM, Juhn AT, Garg SJ, Hsu J, Murchison AP, Spirn MJ. Quality of mydriatic smartphone photography: The Smartphone Ophthalmoscopy Reliability Trial (SORT). *OSLI Retina*. 2015 Jun 1;46(6):631-7.
  37. **Adam MK**, Rahimy E, Dunn JP. Tattoo-Associated Uveitis. *JAMA Ophthalmology*. Apr 9; 133(4): e144543, 2015.

38. **Adam MK**, Pitcher JD, Shields CL, Maguire JI. Enhanced Depth Imaging Optical Coherence Tomography of Precursor Cell Leukemic Choroidopathy Before and After Chemotherapy. *Middle East African Journal of Ophthalmology*. Apr-Jun; 22(2): 249-52, 2015.
39. **Adam MK**, Rahimy E, Brady CJ, Aronsky M, Hsu J, Spirn MJ. Endophthalmitis following penetrating ocular injury in the dentist's chair. *Canadian Journal of Ophthalmology*.49(6): e154-6, 2014.
40. **Adam MK**, Krespen, K, Moster ML, Sergott RC. Simultaneous, Bilateral Ophthalmoplegia as the Presenting Sign of Pediatric Multiple Sclerosis: Case Report and Discussion of the Differential Diagnosis. *Neuro-Ophthalmology*. 38(4): 230-237, 2014.
41. Graves GS, **Adam MK**, Stepien KE, and Han DP. Validation of the Color Difference Plot Scoring Analysis of the 103 Hexagon Multifocal Electroretinogram in the Evaluation of Hydroxychloroquine Retinal Toxicity. *Acta Ophthalmologica*. 92(5):e377-81, 2014.
42. **Adam MK**, Covert DJ, Stepien KE, and Han DP. Quantitative assessment of the 103-hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity. *British Journal of Ophthalmology*. 96(5): 723-729, 2012.
43. Day NF, Kinnischtzke AK, **Adam M**, and Nick TA. Daily and developmental modulation of "premotor" activity in the birdsong system. *Developmental Neurobiology*. 69: 796-810, 2009.
44. Day NF, Kinnischtzke AK, **Adam M**, and Nick TA. Top down regulation of plasticity in the birdsong system: "Premotor" activity in the nucleus HVC predicts song variability better than it predicts song features. *Journal of Neurophysiology*. 100: 2956-2965, 2008.
45. Crandall SR, **Adam M**, Kinnischtzke AK, and Nick TA. HVC neural sleep activity increases with development and parallels nightly changes in behavior. *Journal of Neurophysiology*. 98: 232-240, 2007. Editorial Focus. Cover Article.
46. **Adam M**. Zebra Finch HVC Sleep Activity. Cover Art. *Journal of Neurophysiology*. 98, 2007.

---

#### Non-Peer-Reviewed Publications and Interviews

---

1. Hepp R, **Adam MK**. One to Watch. *Retina Today*. April 2023. (Interview)
2. Ton Nhuong-Sao, **Adam MK**. Managing a Giant Retinal Tear without Vitrectomy. *Retina Today*. November/December 2022.
3. Kitchens JW, **Adam MK**, Rachitskaya A. Matching Patients to Therapy in Wet AMD: Lifestyle Factors that Guide Treatment. *New Retina Radio*. January 2022.
4. **Adam MK** and Garlich J. Keeping Up with Clinical Trials Through Constant Communication. *Retina Today*. November 2021.
5. **Adam MK**. The Five Important Lessons I Learned from Residency. *New Retinal Physician*. July 2021.
6. Stieneker ZN, **Adam MK**. Next Time Will Be Easier – Transitioning Into a Physician-Extender. *Ophthalmic Professional*. July 2021.
7. Joondeph BJ, **Adam MK**. Practice Management Strategies: Are you ready to get LEAN? *Retinal Physician*. November 2020.
8. **Adam MK**, Podesto E. Vitrectomy without Intravenous Anesthesia: Taking cue from our anterior segment colleagues. *Retina Today*. October 2020.
9. Kirby J. Go Lean: Colorado Retina Associates creates patient value with a team-driven efficiency program. *Ophthalmic Professional*. September/October 2020. (Interview and Cover Article)
10. Kitchens JW, **Adam MK**, Almeida DP, Weng CY. New Retina Radio: Are Today's Protocols Tomorrow's Routines? *Retina Today*. September 2020.
11. **Adam MK**. Implementation of Telemedicine in a Retina Practice. *Retinal Physician*. July/August 2020.
12. Mango C, **Adam MK**. Retina Specialists Adjust Practice Policies in Response to Pandemic. Eyewire News. [https://eyewire.news/videos/retina-specialists-adjust-practice-policies-in-response-to-pandemic/] March 2020. (Interview)
13. Ali FS, Wong N, **Adam MK**, Fineman MS. Prefilled syringe opener from a 3D printer. *Retina Today*. October 2019.
14. **Adam MK**, Sheer N. RetinaLink Profile: Murtaza Adam, MD – 3d Heads-Up Display Impressions & Study Results. *RetinaLink* [internet]. October 2018. <https://retinalinkglobal.com/retinalink-profile-murtaza-adam-md-3d-heads-up-impressions-study-results/>

15. Alexander J, Humes A, **Adam MK**, Joondeph BJ. A Simpler Technique for in-office Tap and Injection for Endophthalmitis: Use of a single 27-gauge trocar-cannula port to tap and inject. *Retina Today*. October 2018.
16. **Adam MK**, Klufas MA. Meanwhile, on Eyetube: Gauging Diabetic TRDs. *New Retina MD*. December 2017.
17. **Adam MK**, Ho AC. The Promise and Pitfalls of 3-Dimensional Heads-Up Vitreoretinal Surgery. *Retinal Insider*. September/October 2017.
18. Joshi N, **Adam MK**, Lee DW, Shah VA, Garg SJ. Central Serous Chorioretinopathy: Eye Wiki Informational Page by the American Academy of Ophthalmology [internet]. April 2017. [http://eyewiki.aao.org/Central\\_Serous\\_Chorioretinopathy](http://eyewiki.aao.org/Central_Serous_Chorioretinopathy).
19. **Adam MK**. The Future Awaits. *Retina Today*. April/May 2017.
20. **Adam MK**, Decroos FC, Reed D, Regillo CD. Treat and Extend with Aflibercept for Neovascular AMD: A Rationale for ATLAS. *Retina Times*. April 2017.
21. Sieber M, **Adam MK**, Garg SJ. A Review of Portable Retinal Imaging. *Review of Ophthalmology*. Feb 2017.
22. **Adam MK**, Wykoff C, Hsu J. Opportunities Await. *Retina Today*. Nov/Dec 2016.
23. **Adam MK**, Chiang A, Vander JV. Building a Referral Base: Tips for Newly Graduated Fellows. *Retina Today*. July/Aug 2016.
24. Taney L, Shah V, Thau A, **Adam MK**, Spirn MJ, Gupta OP. Acute Retinal Necrosis: Eye Wiki Informational Page by the American Academy of Ophthalmology [internet]. Oct 2016. [http://eyewiki.aao.org/Acute\\_retinal\\_necrosis](http://eyewiki.aao.org/Acute_retinal_necrosis).
25. Polomsky M, Shah V, Thau A, **Adam MK**, Spirn MJ, Kim J. Acute Posterior Multifocal Placoid Pigment Epitheliopathy: Eye Wiki Informational Page by the American Academy of Ophthalmology [internet]. Oct 2016. [http://eyewiki.aao.org/Acute\\_Posterior\\_Multifocal\\_Placoid\\_Pigment\\_Epitheliopathy](http://eyewiki.aao.org/Acute_Posterior_Multifocal_Placoid_Pigment_Epitheliopathy).
26. Huggins A, Patel J, Melnyk M, Sharma P, Finklea B, Cutler N, Wilson M, Ahmed F, **Adam M**. EyeWorld Journal Club: Femtosecond cataract surgery -- endothelial outcomes. *EyeWorld*, Nov 2014.
27. Morton S, **Adam MK**. Wills Eye Resident Case Series – Idiopathic Polypoidal Choroidal Vasculopathy. *Review of Ophthalmology*, Oct 2014.
28. **Adam MK**. Wills Eye Resident Case Series – Syphilitic Chorioretinitis. *Review of Ophthalmology*. Dec 2013.
29. **Adam MK**. Wills Eye Resident Case Series – Mycobacterial Conjunctivitis. *Review of Ophthalmology*. Jan 2013.

---

## Abstracts / Presentations

---

1. **Adam MK**, Omizo J, Stieneker Z, Kokame G. Combined Pars Plana Vitrectomy with Intraclear Haptic Suture Fixation Versus Sutureless Flange Fixation of Intraocular Lenses: Comparative 6-month Outcomes. American Society of Retina Specialists Annual Meeting. Seattle, WA. July 2023. **Paper on Demand**. (accepted)
2. Zhang A, Dipen K, Tan J, **Adam MK**. Axial Instability of The Zeiss CT Lucia 602 Intraocular Lens with Transconjunctival Intraclear Haptic Fixation. American Society of Retina Specialists Annual Meeting. Seattle, WA. July 2023. **Podium presentation**. (accepted)
3. **Adam MK**, Jain M, Kim E, Shah B, Crowley A, Lee J, Chi G. Clustering and treatment patterns in neovascular age-related macular degeneration and diabetic macular edema: A United States claims database study. ARVO Annual Meeting. New Orleans, LA. April 2023. (accepted)
4. **Adam MK**. Scleral Fixation of Intraocular Lenses: Past, Present, and Future. *Mile High Masters of Retina*. Denver, CO, February 2023. **Podium Presentation**.
5. **Adam MK**. Phacovitrectomy: Combined Pars Plana Vitrectomy and Phacoemulsification Cataract Extraction. *Mile High Masters of Retina*. Denver, CO, February 2023. **Podium Presentation**.
6. **Adam MK**. IV Free is the Way to Be. *Telluride Retina Film Festival*. Telluride, CO, February 2023. **Podium Presentation**.
7. **Adam MK**, Sao T. Endophthalmitis Following Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents with 0.05% Aqueous Chlorhexidine versus 5% Povidone-Iodine as Ocular Antiseptics. *Retina Society Annual Meeting*. Pasadena, CA. November 2022. **Podium presentation**.
8. **Adam MK**. Expressing your passion through innovation. *American Academy of Ophthalmology Annual Meeting*. Chicago, IL. October 2022. **Podium presentation**.



9. Sao T, **Adam MK**. Endophthalmitis Following Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents with 0.05% Aqueous Chlorhexidine versus 5% Povidone-Iodine as Ocular Antiseptics. *American Academy of Ophthalmology Annual Meeting*. Chicago, IL. October 2022.
10. **Adam MK**, Sao T. Endophthalmitis Following Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents with 0.05% Aqueous Chlorhexidine versus 5% Povidone-Iodine as Ocular Antiseptics. *American Society of Retina Specialists Annual Meeting*. New York, NY. July 2022.  
**Podium presentation.**
11. Holekamp N, Sheth VS, **Adam MK**, Lambert J, Lewis HB, Pahwa A, Gentile B, Garmo V, Mirt M. Patient and Caregiver Experience with Anti-VEGF Intravitreal Injections to Treat Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the USA. *American Society of Retina Specialists Annual Meeting*. New York, NY. July 2022
12. **Adam MK**, Holekamp N, Jackson T, Lambert J, Lewis H, Henry-Szatkowski M, Mirt M, Chi GC, Kotecha A, Gentile B. Burden and Impacts Associated with Caring for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema Patients: A Multinational Caregiver Survey. *International Society for Pharmacoeconomics and Outcomes Research*. Fort Washington, MD. May 2022.
13. **Adam MK**, Barras L, Maia M, Gune S, Maass KF, Chang MC. Aqueous humor vascular endothelial growth factor pharmacodynamics in the phase 3 Archway trial of the Port Delivery System with ranibizumab. *ARVO Annual Meeting*. Denver, CO. May 2022. **Podium Presentation.**
14. Sao T, **Adam MK**. Endophthalmitis Following Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents with 0.05% Aqueous Chlorhexidine versus 5% Povidone-Iodine as Ocular Antiseptics. *ARVO Annual Meeting*. Denver, CO. May 2022.
15. Tien K, Podesto E, **Adam MK**. Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes. *ARVO Annual Meeting*. Denver, CO. May 2022.
16. **Adam MK**, Podesto E, Tien K. Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes. *Vit-Buckle Society Annual Meeting*. Las Vegas, NV. March 2022.  
**Podium Presentation.**
17. **Adam MK**. Port Delivery System: The Future for your Patients. *Mile High Masters of Retina*. Denver, CO, February 2022. **Podium Presentation.**
18. **Adam MK**. Masqueraders of Retinal Tumors. *Mile High Masters of Retina*. Denver, CO, February 2022. **Podium Presentation.**
19. **Adam MK**. Bubble Trouble. *Telluride Retina Film Festival*. Telluride, CO, February 2022. **Podium Presentation.**
20. **Adam MK**, Podesto E. Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes. *American Society of Retina Specialists Annual Meeting*. San Antonio, TX, October 2021.
21. Podesto E, **Adam MK**, Hovland PG. Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes. *Retina Society*. Chicago, IL, September 2021.
22. **Adam MK**. Vitrectomy without Intravenous Anesthesia. *University of Alberta – Edmonton Grand Rounds*. January 2021.
23. **Adam MK**. Surgical Management of Zonulopathies. *University of Alberta – Edmonton Grand Rounds*. January 2021.
24. Curran C, **Adam MK**. Outcomes of 3-Piece Poly(methyl methacrylate) Intraocular Lens Rescue and Transconjunctival Intrasceral Lens Fixation. *American Academy of Ophthalmology Annual Meeting*. November 2020.
25. **Adam MK**, Kim E. Anterior and Posterior Segment Research Advancements. *Virtual Visionaries*. October 2020.
26. Lee CS, Hong B, Kasi S, Aderman C, Talcott K, **Adam MK**, Yue B, Akileswaran L, Nakamichi K, Wu Y, Rezaei KA, Olmos de Koo LC, Chee YE, Lee AY, Garg SJ, Van Gelder RN on behalf of the Endophthalmitis Study Group. Prognostic utility of whole genome sequencing and polymerase chain reaction tests of ocular fluids in post-procedural endophthalmitis. *Retina Society*. New York, NY, September 2020.
27. **Adam MK**. Vitreoretinal Surgery: Through the Looking Glass. *Ophthalmic Surgery Grand Grounds*. August 2020.
28. Shukla SS, **Adam MK**. OCT 2.0. *Insight Vision Group Summer CE Series*. August 2020.
29. **Adam MK**. AMD Imposters: The Many Maculopathies that Mimic AMD. *Virtual Visionaries*. May 2020.

30. **Adam MK**, Shukla SS. Epiphany in the Periphery. *Virtual Visionaries*. May 2020.
31. **Adam MK**. Complex Explantation of Scleral Fixated Capsular Devices with Intraocular Lens Exchange. *Telluride Retina Film Festival*. Telluride, CO, February 2020. **Podium Presentation**.
32. **Adam MK**. Surgical Management of Zonulopathies. *Mile High Masters of Retina*. Denver, CO, February 2020. **Podium Presentation**.
33. **Adam MK**. Peripheral Retinal Hemorrhage Pearls. *Mile High Masters of Retina*. Denver, CO, February 2020. **Podium Presentation**.
34. **Adam MK**. Proliferative Diabetic Retinopathy: An Update in the anti-VEGF Era. *Mile High Masters of Retina*. Denver, CO, February 2020. **Podium Presentation**.
35. **Adam MK**. Vitrectomy is the Best Option for Symptomatic Vitreous Floaters. *Wills Eye Hospital Retina Update*. Philadelphia, PA, November 2019. **Podium Presentation**.
36. **Adam MK**, Leonard J. Surgical Outcomes of Simultaneous Rigid 3-Piece Poly(methyl methacrylate) Intraocular Lens Rescue and Sutureless Flanged Intrascleral Lens Fixation. *ASRS Annual Meeting*. Chicago, IL, August 2019.
37. **Adam MK**. Simultaneous Rigid 3-Piece Poly(methyl methacrylate) Intraocular Lens Rescue, Haptic Modification, and Sutureless Flanged Intrascleral Lens Fixation. *Vit-Buckle Society Annual Meeting*. Las Vegas, NV, April 2019. **Podium presentation**.
38. **Adam MK**. Complex Anterior Segment Surgery for the Posterior Segment Surgeon. *Spring Vision Congress*. Parker, CO, March 2019.
39. **Adam MK**. Complex Anterior Segment Surgery for the Posterior Segment Surgeon. *Mile High Masters of Retina*. Denver, CO, February 2019.
40. **Adam MK**. Vitrectomy is the Best Option for Symptomatic Vitreous Floaters. *Wills Eye Hospital Retina Update: Controversies in Retina*. Philadelphia, PA, December 2018. **Podium Presentation**.
41. **Adam MK**, Zheng CX, Fineman MS. The Impact of Periocular Vibration Anesthesia on Pain Perceived During Intravitreal Injections. *American Academy of Ophthalmology Annual Meeting*. Chicago, IL, October 2018.
42. Zheng CX, **Adam MK**, Fineman MS. The Impact of Periocular Vibration Anesthesia on Corneal and Conjunctival Anesthesia. *American Academy of Ophthalmology Annual Meeting*. Chicago, IL, October 2018.
43. **Adam MK**, Talcott KE, Soufi K, Aderman CM, Ali FS, Mellen PL, Garg SJ, Hsu J, Ho AC. Comparison of Three-Dimensional Heads-Up Display Platform to Standard Operating Microscope for Macular Surgery. *Retina Society*. San Francisco, CA, September 2018. **Podium Presentation**.
44. Obeid A, Ehmann D, **Adam MK**, Kasi S, Klufas M, Hsu J, Mehta S, Chiang A, Garg SJ, Gupta OG. Comparison of Residual Subfoveal Fluid By Intraoperative Optical Coherence Tomography After Macula Involving Rhegmatogenous Retinal Detachment Repair Using Direct Drainage, Drainage Retinotomy, or Pefluoro-n-Octane. *Retina Society*. San Francisco, CA, September 2018.
45. Sharma P, Kasi SK, **Adam MK**, Dunn JP. Sudden Bilateral Vision Loss. Case on Demand. *ASRS Annual Meeting*, Vancouver, Canada, July 2018.
46. Cutler N, Shahlaee A, **Adam MK**. En Face versus 25-line Raster Optical Coherence Tomography Scan Patterns for Detection of Macular Fluid in Retinal Vein Occlusions and Central Serous Retinopathy. *ARVO Annual Meeting*, Honolulu, HI, April 2018.
47. Obeid A, Ehmann D, **Adam MK**, Kasi S, Klufas M, Hsu J, Mehta S, Chiang A, Garg SJ, Gupta OG. Comparison of Residual Subfoveal Fluid By Intraoperative Optical Coherence Tomography After Macula Involving Rhegmatogenous Retinal Detachment Repair Using Direct Drainage, Drainage Retinotomy, or Pefluoro-n-Octane. *ARVO Annual Meeting*, Honolulu, HI, April 2018.
48. **Adam MK**. The Future of Vitreoretinal Surgery. *Mile High Masters of Retina*. Denver, CO, February 2018. **Podium Presentation**.
49. **Adam MK**. Diabetic Retinopathy for the Family Doctor. *48<sup>th</sup> Annual Winter Refresher Course*. Milwaukee, WI, February 2018. **Podium Presentation**.
50. **Adam MK**. Dinner and a Show: Weird and Whacky Retina Cases. Boulder, CO December 2017.
51. **Adam MK**. Digitally Augmented Vitreoretinal Surgery: Fad or the Future? *Wills Eye Hospital Retina Update: Global Advances in Medical and Surgical Retina*. Philadelphia, PA, December 2017. **Podium Presentation**.
52. Thau A, Tsukikawa T, Wangtiraumnay N, Capasso J, Affel L, Abed Alnabi W, **Adam M**, Alsulaiman S, Spirn M, Levin AV. Optical Coherence Tomography in Knobloch Syndrome. *American Association for Pediatric Ophthalmology and Strabismus*, Washington DC, March 2018.

53. **Adam MK.** The Not So Immaculate Macula. *Colorado Retina Associates Technician Lecture Series.* Denver, CO, October 2017.
54. Thau A, Tsukikawa T, Wangtiraumnuy N, Capasso J, Affel L, Abed Alnabi W, **Adam M,** Alsulaiman S, Spirn M, Levin AV. Optical Coherence Tomography in Knobloch Syndrome. *International Society for Genetic Eye Diseases and Retinoblastoma,* Leeds, England, September 2017.
55. **Adam MK.** Retinal Disease Research Update: Hope on the Horizon. *VisionWalk Kickoff Meeting.* Denver, CO, August 2017.
56. Obeid A, Gao X, Aderman C, Ali F, **Adam MK,** Hsu J, Ho AC. Comparison of follow-up compliance rates between pan-retinal photocoagulation and intravitreal injections in patients with proliferative diabetic retinopathy. *Retina Society Annual Meeting,* Boston, MA, 2017.
57. Sharma P, Pefkianaki M, **Adam MK,** Ho AC, Hsu J, Maguire JI, Regillo CD, Affel C, Affel L, Haller JA. Optical Coherence Tomography Angiography and Dark Adaptation in Screening and Diagnosis of Hydroxychloroquine Toxicity. *Retina Society Annual Meeting,* Boston, MA, 2017.
58. Sieber MR, Shahlaee A, **Adam MK,** Cohen MC, Houston SK, Federman JL, Gupta OP. Quality and Utility of a Portable Anterior Segment and Non-mydratic Fundus Camera Linked to a Smartphone-Based Virtual Consultation Platform. *Retina Society Annual Meeting,* Boston, MA, 2017.
59. Aderman C, Joshi N, **Adam MK,** Samara WA, Shahlaee A, Hsu J, Fineman MS, Garg SJ. Optical density of subretinal fluid in patients with chronic central serous chorioretinopathy treated with eplerenone: a potential imaging biomarker. *Retina Society Annual Meeting,* Boston, MA, 2017.
60. Sharma P, Pefkianaki M, **Adam MK,** Ho AC, Hsu J, Maguire JI, Regillo CD, Affel C, Affel L, Haller J. Optical Coherence Tomography Angiography and Dark Adaptation in Screening and Diagnosis of Hydroxychloroquine Toxicity. *ASRS Annual Meeting,* Boston, MA, 2017.
61. Sharma P, Pefkianaki M, **Adam MK,** Ho AC, Hsu J, Maguire JI, Regillo CD, Affel C, Affel L, Haller J. Optical Coherence Tomography Angiography in Hydroxychloroquine Toxicity. *ARVO Annual Meeting,* Baltimore, MD, 2017.
62. Sieber MR, Shahlaee A, **Adam MK,** Cohen MC, Houston SK, Federman JL. Quality and Utility of a Portable Anterior Segment and Non-mydratic Fundus Camera Linked to a Smartphone-Based Virtual Consultation Platform. *ARVO Annual Meeting,* Baltimore, MD, 2017.
63. Cutler N, Shahlaee A, **Adam MK,** Hsu J. Effectiveness of en face spectral domain optical coherence tomography for detection of diabetic macular edema. *ARVO Annual Meeting,* Baltimore, MD, 2017.
64. Kuley B, Jenkins T, **Adam MK,** Hsu J, Garg SJ. Optical Subretinal Fluid Density as a Prognostic Biomarker for Macula Off Rhegmatogenous Retinal Detachment. *ARVO Annual Meeting,* Baltimore, MD, 2017.
65. Joshi N, **Adam MK,** Samara WA, Shahlaee A, Rahimy E, Hsu J, Fineman MS, Garg SJ. Optical density of subretinal fluid in patients with chronic central serous chorioretinopathy treated with eplerenone: a potential imaging biomarker. *ARVO Annual Meeting,* Baltimore, MD, 2017.
66. Weinstock BM, **Adam MK,** Kasi S, Ehmann DS, Hsu J, Garg SJ, Ho AC, Chiang A. Patient comfort using green (532 nm) versus yellow (577 nm) laser indirect ophthalmoscopy panretinal photocoagulation for proliferative diabetic retinopathy. *ARVO Annual Meeting,* Baltimore, MD, 2017.
67. Stephens D, **Adam MK,** Garg SJ, Mehta S. Optical Coherence Tomography Features of Endogenous Fungal Chorioretinitis and Endophthalmitis. *Wills Eye Conference Free Paper Session,* Philadelphia, PA 2017.
68. Sieber MR, Shahlaee A, **Adam MK,** Federman JL. Quality and Utility of a Portable Anterior Segment and Non-mydratic Fundus Camera Linked to a Smartphone-Based Virtual Consultation Platform. *Wills Eye Conference Free Paper Session,* Philadelphia, PA 2017.
69. Sharma P, Pefkianaki M, **Adam MK,** Haller JA. Optical Coherence Tomography Angiography and Dark Adaptation in Screening of Hydroxychloroquine Toxicity. *Wills Eye Conference Free Paper Session,* Philadelphia, PA 2017.
70. Cutler N, Shahlaee A, **Adam MK,** Hsu J. Effectiveness of en face spectral domain optical coherence tomography for detection of diabetic macular edema. *Wills Eye Conference Free Paper Session,* Philadelphia, PA 2017.
71. Jenkins T, Kuley B, **Adam MK,** Garg SJ. Optical Subretinal Fluid Density as a Prognostic Biomarker for Macula Off Rhegmatogenous Retinal Detachment. *Wills Eye Conference Free Paper Session,* Philadelphia, PA 2017.

72. **Adam MK**, Aenchbacher W, Kurzweg T, Hsu J. Adaptation of Light-Field Cameras for Mydriatic Plenoptic Ophthalmoscopy. *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2017.
73. Weinstock BM, **Adam MK**, Kasi S, Ehmann DS, Hsu J, Garg SJ, Ho AC, Chiang A. Patient comfort using green (532 nm) versus yellow (577 nm) laser indirect ophthalmoscopy panretinal photocoagulation for proliferative diabetic retinopathy. *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2017.
74. **Adam MK**. Vitreoretinal Surgery Fellowships: A Fresh Perspective. *Mile High Masters of Retina*, Denver, CO, 2017.
75. Shahlaee A, Samara WA, **Adam MK**, Chiang A, Maguire JI, Ho AC, Hsu J. Comparison of Optical Coherence Tomography Angiography Biomarkers for Distinguishing Diabetic Subjects with Varying Levels of Retinopathy from Non-diabetic Healthy Controls. *American Academy of Ophthalmology Annual Meeting*, Chicago, IL, 2016.
76. Samara WA, Shahlaee WA, **Adam MK**, Chiang A, Maguire JI, Hsu J, Ho AC. Quantification of Diabetic Macular Ischemia using OCT Angiography and its Relationship with Visual Function. *American Academy of Ophthalmology Annual Meeting*, Chicago, IL, 2016.
77. Shahlaee A, Samara WA, **Adam MK**, Chiang A, Maguire JI, Ho AC, Hsu J. Comparison of Optical Coherence Tomography Angiography Biomarkers for Distinguishing Diabetic Subjects with Varying Levels of Retinopathy from Non-diabetic Healthy Controls. *Retina Society Annual Meeting*, San Diego, CA, 2016.
78. **Adam MK**, DeCroos FC, Reed D, Salz D, Gupta OP, Ho AC, Shields CL, Regillo CD. Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration (ATLAS): 2 Year Results. *Retina Society Annual Meeting*, San Diego, CA, 2016. **Podium Presentation**.
79. **Adam MK**, Thornton S, Ho AC, Hsu J, Endoillumination Levels and Display Luminous Emittance During Three-Dimensional Heads-Up Vitreoretinal Surgery. *ASRS Annual Meeting*, San Francisco, CA, 2016.
80. Reed D, DeCroos FC, **Adam MK**, Salz D, Gupta OP, Ho AC, Regillo CD. Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration (ATLAS): 2 Year Results. *ASRS Annual Meeting*, San Francisco, CA, 2016.
81. Shahlaee A, Samara WA, **Adam MK**, Chiang A, Maguire JI, Ho AC, Hsu J. Comparison of Optical Coherence Tomography Angiography Biomarkers for Distinguishing Diabetic Subjects with Varying Levels of Retinopathy from Non-diabetic Healthy Controls. *Cole Eye Imaging Summit*, San Francisco, CA, 2016.
82. Durrani A, **Adam MK**, Calvo C, Murchison AP. Community emergency department referral patterns, diagnostic accuracy, and initial management of patients referred to a tertiary emergency eye care department. *ARVO Annual Meeting*, Seattle, WA, 2016.
83. **Adam MK**, Shahlaee A, Hsu J. En-face versus 12-line radial spectral domain optical coherence tomography scan patterns for detection of neovascular age-related macular degeneration pathology. *ARVO Annual Meeting*, Seattle, WA, 2016.
84. Thornton S, **Adam MK**, Ho AC, Hsu J, Endoillumination Levels and Display Luminous Emittance During Three-Dimensional Heads-Up Vitreoretinal Surgery. *ARVO Annual Meeting*, Seattle, WA, 2016.
85. DeCroos FC, Reed D, **Adam MK**, Salz D, Gupta OP, Ho AC, Regillo CD. Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration (ATLAS): 2 Year Results. *ARVO Annual Meeting*, Seattle, WA, 2016.
86. **Adam MK**. Fellow Surgical Case. *Duke Advanced Vitreoretinal Surgery Course*. Durham, NC, 2016.
87. **Adam MK**. Mystery Case. *Atlantic Coast Retina Club*. New York, NY, 2016. **Podium Presentation**.
88. **Adam MK**, Gupta OP, Ho AC, Regillo CD. Aflibercept Treat and Extend Therapy for Neovascular Age-Related Macular Degeneration (ATLAS): 2 Year Results. *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2016. **Podium Presentation**.
89. **Adam MK**, Brady CJ, DellaVecchia M, Garg S, Spirn M, Kurzweg T, Hsu J. Mydriatic Plenoptic Ophthalmoscopy: A Novel Fundus Imaging Technique. *ARVO Imaging Conference*, Denver, CO 2015.
90. Rahimy E, **Adam MK**, Rayess N, Maguire JI, Hsu J. Radial Versus Raster Spectral-Domain Optical Coherence Tomography Scan Patterns for Detection of Neovascular Age-Related Degeneration Disease Activity. *ARVO Annual Meeting*, Denver, CO, 2015.

91. Vahedi S, **Adam MK**, Dollin M, Maguire J. Utilization of a 25-Gauge Trocar for Vitreous Tap and Injection in Eyes with Endophthalmitis. *ARVO Annual Meeting*, Denver, CO, 2015.
92. Ahmed F, Intili A, Vahedi S, **Adam MK**, Feldman B, Uhler T. Consultations for Post-Operative Eye Pain Following Non-Ocular Surgery at a Tertiary Teaching Hospital. *ARVO Annual Meeting*, Denver, CO, 2015.
93. **Adam MK**, Aenchbacher W, Kurzweg T, Hsu J. Mydriatic Fundus Plenoptic Photography: A Novel Imaging Technique. *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2015.
94. Durrani A, **Adam MK**, Calvo C, Murchison AP. Referral patterns and diagnostic accuracy of patients referred to an eye emergency room. *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2015.
95. Flowers AM, **Adam MK**, Sergott RJ. Retrospective Comparison of mfERG and OCT between RRMS and PPMS Patients with and without Optic Neuritis. *2014 Joint ACTRIMS-ECTRIMS Meeting*, Boston, MA 2014.
96. **Adam MK**, Brady CJ, Flowers AM, Juhn AT, Garg SJ, Hsu J, Murchison AP, Spirn MJ. Quality of mydriatic smartphone photography: Preliminary Results from the Smartphone Ophthalmoscopy Reliability Trial (SORT). *ASRS Annual Meeting*, San Diego, CA, 2014.
97. **Adam MK**, Nichols MM, Vahedi S, Fintelmann RE, Keenan JD, Garg SJ, Hsu J, Spirn MJ, Maguire, JI. Inpatient Ophthalmology Consultation for Fungemia: Prevalence of Ocular Involvement and Necessity of Funduscopy Screening. *Retina Society Annual Meeting*, Philadelphia, PA, 2014.
98. **Adam MK**, Brady CJ, Flowers AM, Juhn AT, Garg SJ, Hsu J, Murchison AP, Spirn MJ. Quality of mydriatic smartphone photography: Preliminary Results from the Smartphone Ophthalmoscopy Reliability Trial (SORT). *ARVO Annual Meeting*, Orlando, FL, 2014.
99. Nichols MM, Vahedi S, **Adam MK**, Fintelmann RE, Keenan JD, Garg SJ, Hsu J, Spirn MJ. Inpatient Ophthalmology Consultation for Fungemia: Prevalence of Ocular Involvement and Necessity of Funduscopy Screening. *ARVO Annual Meeting*, Orlando, FL, 2014.
100. Flowers AM, **Adam MK**, Sergott RJ. Retrospective Correlation of mfERG and OCT between RRMS and PPMS Patients with and without Optic Neuritis. *Sigma Xi Research Day*, Philadelphia, PA, 2014.
101. **Adam MK**, Brady CJ, Murchison AP, Spirn MJ. Quality of mydriatic smartphone photography: The Smartphone Ophthalmoscopy Reliability Trial (SORT). *Wills Eye Conference Free Paper Session*, Philadelphia, PA 2014. **Podium Presentation.**
102. **Adam MK**. Mystery Case. *Atlantic Coast Retina Club*. Philadelphia, PA, 2014. **Podium Presentation.**
103. Graves G, **Adam MK**, Stepien KE, Han DP. Validation of the Color Difference Plot Scoring Analysis of the 103 Hexagon Multifocal Electroretinogram in the Evaluation of Hydroxychloroquine Retinal Toxicity. *ARVO Annual Meeting*, Ft. Lauderdale, FL, 2012.
104. Han DP, **Adam MK**, Covert DJ, Stepien KE. Quantitative assessment of the 103-hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity. *ARVO Annual Meeting*, Ft. Lauderdale, FL, 2011.
105. **Adam M**, Gerges N. The role of neurogranin in Alzheimer's disease. *Medical College of Wisconsin 2008 Medical Student Summer Research Program*. Milwaukee, WI, 2008.
106. Nick TA, Kinnischtzke AK, **Adam M**. Rhythmic spiking in HVC during singing increases during the day and decreases after a night of sleep. *Eighth International Congress of Neuroethology Abstracts*, Vancouver, BC, 2007.
107. Kinnischtzke, AK, **Adam MK**, Crandall SR, Nick TA. Investigation of the role of sleep activity in the vocal development of the zebra finch. *University of Minnesota Presidential Symposium on Neuroscience*, Minneapolis, MN, 2006.

---

## Surgical Videos

---

1. **Adam MK**, Chen R. A Challenging IOL Dislocation. *EyeTube*. March 2019.
2. **Adam MK**, Vander JM. A Far Reach: PPV in Highly Myopic Eyes. *Retina Specialist*. February 2019.
3. **Adam MK**. A Hybrid Vitrectomy. *EyeTube*. November 2017.
4. **Adam MK**, Garg SJ. The Neverending Learning Curve. *EyeTube*. November 2017.
5. **Adam MK**, Hsu J. Intraoperative OCT of Inverted Internal Limiting Membrane Flap. *American Academy of Ophthalmology ONE Network*. October 2017.

6. **Adam MK**, Garg SJ. Displacement of Submacular Hemorrhage. *American Academy of Ophthalmology ONE Network*. Editor's Choice. January 2017.
7. **Adam MK**, Park C. Macular Translocation for Neovascular AMD. *American Academy of Ophthalmology ONE Network*. Editor's Choice. December, 2016.
8. **Adam MK**, Fineman MS. Externalized Gore-Tex Suture Rescue Technique. *American Academy of Ophthalmology ONE Network*. Editor's Choice. December 2016.